Genomic Vision propose des solutions fondées sur
l’analyse structurale de l’ADN et des tests génétiques
dans les domaines du cancer, des maladies héréditaires
rares et de la pharmaco-génomique.
Ph.D., Vice President
Dr Camille Chypre has over 25 years of international experience in the development of innovative In Vitro Diagnostic tests for European and US market in large companies and start up.
In 1989 he began its career at CIS bio international (subsidiary of CEA-Industry) as research engineer and then occupied various management positions. He developed innovative IVD products based on PCR technology and CEA technology
In 1997 he joined DiagnoCure Inc. , a Canadian start up based at Quebec city, as Molecular Biology director and successively occupied the positions of R&D Director and R&D Vice-President. In charge of the development of molecular innovative test in oncology he is the co-inventor of an innovative test to detect prostate cancer cells in urine based on the detection of non-coding PCA3 gene RNAs. This test named PROGENSA PCA3 is currently commercialized by Hologic Inc.
In 2005 he joined Bio-Rad Inc. as Business Unit manager. In charge to create a new product line to detect infectious disease by molecular biology technologies , he developed new instruments for DNA extraction and Real time PCR amplification as well software solutions and innovative multiplex Real time PCR kits for the detection of Mycobacteria tuberculosis , Chlamydia trachomatis / Neisseria gonorrhea /Mycoplasma genitallium and High-Risk Human Papillomavirus.
In July 2015 he joined Genomic Vision as R&D Vice-President.
Dr Camille Chypre is a biochemist engineer (INSA Lyon) and has a doctorate In Molecular and Cellular biology from Strasbourg university as well a degree in Pharmacology and Toxicology of Lyon University.